普衡律师事务所、富而德律师事务所、贝克·麦坚时国际律师事务所近日在两起跨境抗疫合作中扮演了关键性角色。

普衡代表上海复星医药与德国BioNTech公司签订战略合作协议,将利用BioNTech的mRNA候选疫苗BNT162开发并商业化一种预防新冠病毒感染的疫苗产品,富而德则为BioNTech提供了法律咨询。

根据协议,复星医药将向合作方支付最多8500万美元的许可费,同时认购BioNTech价值5000万美元的股份。复星医药将利用自身在中国的临床开发、监管合规及商业能力,联合开发并推动疫苗在中国的临床试验。

与此同时,贝克·麦坚时则代表美国医疗器械制造商CytoSorbents公司,与中国康哲药业达成协议,向中国引进CytoSorb体外细胞因子吸附器以治疗新冠肺炎重症患者。双方将共同应对中国国家药品监督管理局的审查程序,首批CytoSorb吸附器将由CytoSorbents捐赠并提供产品培训,将用于武汉的四家医院。

普衡团队牵头律师为京沪办事处联合管理合伙人严嘉,并由华盛顿特区合伙人Scott Flicker及法兰克福合伙人Regina Engelstädter提供协助;富而德团队牵头律师为合伙人Peter Versteegen;贝克·麦坚时团队则包括合伙人Oren Livne、刘芳君、屈爱青及李心雯律师。

 

Paul Hastings, Freshfields, Bakers act on cross-border cooperation to combat COVID-19 

Paul Hastings, Freshfields Bruckhaus Deringer and Baker McKenzie have taken leading roles on two Sino-German and Sino-U.S. cooperation to combat the outbreak of coronavirus in China.

Paul Hastings has advised China healthcare group Fosun Pharma on its strategic agreement with German biopharmaceutical company BioNTech to develop and commercialize a vaccine that prevents COVID-19 infections. Freshfields advised BioNTech in the deal.

The vaccine will use BioNTech’s mRNA vaccine candidate BNT162. According to the agreement, Fosun Pharma will pay at most $85 million as licensing fees. It will also make an equity investment of $50 million in the German company. Fosun Pharma will use its clinical development, regulatory, and commercial capabilities in the country to promote the conduction of clinical trials of the vaccine.

Meanwhile, Baker McKenzie has acted for U.S. medical instrument producer CytoSorbents on its agreement with China Medical System Holdings (CMS) to bring CytoSorb, a product to reduce the "cytokine storm", to China to treat critically ill patients with COVID-19 infection. They will partner together to earn regulatory clearance, and CytoSorbents will donate initial devices and provide product, training, and support to CMS to introduce CytoSorb into four hospitals in Wuhan.

The Paul Hastings team was led by partner and co-chair of the firm’s mainland China offices Yan Jia, with support from Washington D.C. partner Scott Flicker and Frankfurt partner Regina Engelstaedter, while the Freshfields team by partner Peter Versteegen. The Baker McKenzie team included partners Oren Livne, Isabella Liu, Tracy Wut, and Christina Lee.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

华润饮料拟赴港上市(ZH/EN)

by Charlie Wu 吴卓言 |

华润饮料(控股)有限公司(华润饮料)已于4月22日向香港联合交易所递交上市申请。自2022年以来,华润饮料几度被传筹备推动华润饮料赴港上市,据彭博报道,该项目募资规模或达 10 亿美元。

通商、竞天公诚、君合等领衔助力第四范式、十月稻田香港上市(ZH/EN)

近日,香港资本市场迎来多宗重要上市项目,其中AI公司第四范式于国庆假期前登陆港交所,募资约1.07亿美元;食品品牌十月稻田则在假期后完成上市,募资约1.05亿美元。

七家律所参与香港首宗De-SPAC并购交易(ZH/EN)

by Mari Iwata |

近日,中国钢铁电商平台找钢产业互联集团(“找钢网”)与特殊目的收购公司(SPAC)Aquila Acquisition Corporation进行业务合并,成为自2022年1月1日香港引入SPAC上市机制以来香港首个SPAC并购交易,Aquila也是首家在香港上市的SPAC。